Literature DB >> 28325568

Prevalence and Management of Systemic Hypertension in Athletes.

Stefano Caselli1, Antonia Vaquer Sequì2, Erika Lemme2, Filippo Quattrini2, Alberto Milan3, Flavio D'Ascenzi4, Antonio Spataro2, Antonio Pelliccia2.   

Abstract

The aim of the present study was to evaluate the prevalence, determinants, and clinical management of systemic hypertension in a large cohort of competitive athletes: 2,040 consecutive athletes (aged 25 ± 6 years, 64% men) underwent clinical evaluation including blood test, electrocardiogram, exercise test, echocardiography, and ophthalmic evaluation. Sixty-five athletes (3%) were identified with hypertension (men = 57; 87%) including 5 with a secondary cause (thyroid dysfunction in 3, renal artery stenosis in 1, and drug induced in 1). The hypertensive athletes had greater left ventricular hypertrophy and showed more often a concentric pattern than normotensive ones. Moreover, they showed a mildly reduced physical performance and were characterized by a higher cardiovascular risk profile compared with normotensive athletes. Multivariate logistic regression analysis showed that family hypertension history (odds ratio 2.05; 95% confidence interval 1.21 to 3.49; p = 0.008) and body mass index (odds ratio 1.32; 95% confidence interval 1.23 to 1.40; p <0.001) were the strongest predictors of hypertension. Therapeutic intervention included successful lifestyle modification in 57 and required additional pharmacologic treatment in 3 with essential hypertension. Secondary hypertension was treated according to the underlying disorder. After a mean follow-up of 18 ± 6 months, all hypertensive athletes had achieved and maintained optimal control of the blood pressure, without restriction to sport participation. In conclusion, the prevalence of hypertension in athletes is low (3%) and largely related to family history and overweight. In the vast majority of hypertensives, lifestyle modifications were sufficient to achieve an optimal control of blood pressure values.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28325568     DOI: 10.1016/j.amjcard.2017.02.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Brachial and central blood pressure and arterial stiffness in adult elite athletes.

Authors:  Fabian Tomschi; Hannah Ottmann; Wilhelm Bloch; Marijke Grau; Hans-Georg Predel
Journal:  Eur J Appl Physiol       Date:  2021-03-13       Impact factor: 3.078

2.  Sleep, napping and alertness during an overwintering mission at Belgrano II Argentine Antarctic station.

Authors:  Agustín Folgueira; Guido Simonelli; Santiago Plano; Camila Tortello; Juan Manuel Cuiuli; Abel Blanchard; Alejandro Patagua; Allison J Brager; Vincent F Capaldi; André E Aubert; Marta Barbarito; Diego A Golombek; Daniel E Vigo
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

3.  Exercise Training Attenuates Hypertension Through TLR4/MyD88/NF-κB Signaling in the Hypothalamic Paraventricular Nucleus.

Authors:  Jie Qi; Xiao-Jing Yu; Li-Yan Fu; Kai-Li Liu; Tian-Tian Gao; Jia-Wei Tu; Kai B Kang; Xiao-Lian Shi; Hong-Bao Li; Ying Li; Yu-Ming Kang
Journal:  Front Neurosci       Date:  2019-10-24       Impact factor: 4.677

Review 4.  Athletes and Hypertension.

Authors:  Victor Schweiger; David Niederseer; Christian Schmied; Christine Attenhofer-Jost; Stefano Caselli
Journal:  Curr Cardiol Rep       Date:  2021-10-16       Impact factor: 2.931

5.  Systolic Blood Pressure Response to Exercise in Endurance Athletes in Relation to Oxygen Uptake, Work Rate and Normative Values.

Authors:  Anna Carlén; Gustaf Eklund; August Andersson; Carl-Johan Carlhäll; Magnus Ekström; Kristofer Hedman
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-15

6.  Resting Electrocardiogram and Blood Pressure in Young Endurance and Nonendurance Athletes and Nonathletes.

Authors:  Heikki Pentikäinen; Kerttu Toivo; Sami Kokko; Lauri Alanko; Olli J Heinonen; Raija Korpelainen; Harri Selänne; Tommi Vasankari; Urho M Kujala; Jari Villberg; Jari Parkkari; Kai Savonen
Journal:  J Athl Train       Date:  2021-05-01       Impact factor: 2.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.